引用第5楼florid于2007-08-05 21:29发表的:温主任带硕士，不过若是女生恐怕收下的难度比较大，若是男生应该比较容易，温主任想要个男生久已。另外，温主任重临床轻科研，现在已经取消了博士的科研经费，以后会陆续取消硕士的经费，如果导师没有经费，课题会比较难办。.......
钱还是有的，总不能让学生自己掏钱答辩了，reputation还是很重要的。好歹也是全国重点大学山东大学的七年制的。
2005年的时候有经费40万（温泽清 妇科肿瘤 省重点课题1项,卫生厅课题1项,经费合计40余万 科研能力强或微创技术能力强）
http://www.rsc.sdu.edu.cn/2005new/CMS/articlesattach/050420083912.doc2006年的时候还有经费30万（温泽清 卵巢肿瘤基因转导 妇科肿瘤 省科技厅课题30万 年龄35岁以下男性临床医学）
http://www.medicine.sdu.edu.cn/chinese/boshihou/wenjian/%C1%D9%B4%B2%D2%BD%D1%A72006%C4%EA%B2%A9%CA%BF%BA%F3%D5%D0%CA%D5%BC%C6%BB%AE(%C9%CF%B1%A8).doc
2007年经费又是40万
(山东省立医院妇科学 温泽清 妇科肿瘤基础研究和临床手术治疗学 妇科肿瘤 40万 省级 临床医学）
http://www.medicine.sdu.edu.cn/chinese/boshihou/wenjian/2007/2007%C4%EA%C1%D9%B4%B2%D2%BD%D1%A7%B2%A9%CA%BF%BA%F3%D5%D0%CA%D5%BC%C6%BB%AE.docPUBMED/SCI检索到2篇
1: Eur J Haematol. 2007 May;78(5):432-9.
Optimization of multidrug resistance 1 gene transfer confers chemoprotection to
human hematopoietic cells engrafted in immunodeficient mice.
Zhang H, Wen Z, Tan S, Li C, Lan S, Li J.
Department of Obstetrics and Gynecology, Shandong Provincial Hospital, Shandong
University School of Medicine, Jinan, Shandong, China.
OBJECTIVE: To investigate whether an optimization of MDR1 gene transfer protocol
would result in stable hematopoietic stem cell (HSC) engraftment and
myeloprotection in non-obese diabetic/severe combined immunodeficient (NOD/SCID)
mice after paclitaxel chemotherapy. METHODS: We transplanted freshly isolated
CD34+ cells or MDR1-transduced CD34+ cells derived from human umbilical cord
blood (UCB) into sublethally irradiated NOD/SCID mice. Twenty-eight days after
transplantation, mice received paclitaxel chemotherapy and peripheral blood (PB)
was collected for analysis of WBC, RBC and PLT counts once every week. RESULTS:
We found that MDR1-transduced human hematopoietic cells could facilitate
hematopoietic recovery and completely reconstitute hematopoiesis in mice as well
as freshly isolated CD34+ cells. Mice transplanted with MDR1-transduced human
hematopoietic cells were protected from paclitaxel chemotherapy with higher
survival rate and higher level of WBC counts and RBC counts compared with mice
transplanted with untransduced HSCs. We also demonstrated that hematopoietic
cells transduced with MDR1 gene were enriched in vivo after paclitaxel
chemotherapy determined by the higher percentage of human Rh-123(dull) CD45+
cells in bone marrow of mice. CONCLUSION: Our results demonstrated successful
chemoprotection against myelosuppression in mice by MDR1-transduced repopulating
human hematopoietic cells with an optimized transduction protocol.
Publication Types:
Research Support, Non-U.S. Gov't
PMID: 17331135 [PubMed - indexed for MEDLINE]
2: Neoplasma. 2007;54(1):21-8.
The AFT024 stromal cell line improves MDR1 gene transfer to CD34+ cells derived
from human umbilical cord blood.
Zhang H, Wen Z, Lan S, Li C, Li J, Zhang X.
Shandong Provincial Hospital, Shandong University, Jinan, PR China.
Human hematopoietic stem cells (HSCs) are difficult to transfect with retroviral
vectors because of their quiescent nature. Based on the theory that the murine
fetal stromal cell line AFT024 can recruit significant numbers of HSC into cell
cycle without loss of their primitive function, we transduced human umbilical
cord blood cells (UCB) derived CD34+ cells with a retroviral vector pHaMDR1/A
containing the human multidrug resistant 1 gene (MDR1) during co-culture with the
AFT024 feeders. We found that the presence of the AFT024 cells increased the
proportion of Rh-123dull cells up to 35.5%+/-11.4% and transduced colony-forming
cells (CFCs) up to 15.2%. Six weeks after transplantation of 5x10(4) day 0
uncultured CD34+ HSCs or their equivalents expanded in the presence or absence of
the AFT024 cells for 21 days into non-obese diabetic/severe combined
immunodeficient (NOD/SCID) mice, we found that CD34+ cells expanded in the
presence of the AFT024 cells engrafted in each receptor mouse and the percentage
of CD45+ cells reached 18.8%+/-9.5%, of which 18.1%+/-6.0% were Rh-123dull cells.
These results suggest that the AFT024 stromal cells can significantly improve
MDR1 gene transfer efficiency and maintain the engrafting ability of the CD34+
HSCs derived from UCB.
Publication Types:
Research Support, Non-U.S. Gov't
PMID: 17203889 [PubMed - indexed for MEDLINE]
